Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Protara Therapeutics, Inc. (TARA)

Protara Therapeutics Q3 net loss widens to $21.7 million from $13.3 million

Negative Impact 3 of 5 earnings

Protara Therapeutics reported third quarter 2026 results, with a net loss of $21.7 million, or $0.35 per share, compared with a net loss of $13.3 million, or $0.31 per share, a year earlier. Research and development expenses rose to $16.8 million from $9.6 million, and the company said cash, cash equivalents and marketable debt securities of $143.1 million should fund operations into 2028.

Key points

  • Q3 2026 net loss of $21.7 million ($0.35 per share) vs. $13.3 million ($0.31 per share) in Q3 2025
  • R&D expenses rose to $16.8 million from $9.6 million, mainly from higher clinical trial costs of $4.4 million
  • Cash and marketable debt securities totaled $143.1 million as of September 30, 2026
  • On November 4, 2026, the company agreed to buy TARA-002 manufacturing-related assets from Novex Innovations for $8.75 million

The filing

CompanyProtara Therapeutics, Inc. (TARA)
Form8-K, current report
Filed with the SECNov 6, 2026, 8:05 AM ET
Accession number0001213900-26-116607

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.